Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer

Carcinoembryonic antigen (CEA) affects tumorigenesis by enhancing tumor cell survival and by inducing tumor angiogenesis. This study aimed to evaluate baseline CEA serum levels to predict bevacizumab‐based therapy effect and survival in patients with metastatic colorectal cancer (mCRC). Two hundred and ninety eight mCRC patients receiving chemotherapy plus either bevacizumab or cetuximab were analyzed in a retrospective study. Disease control (DC), progression‐free survival (PFS), and overall survival were assessed and related to pretreatment CEA serum levels. Patients with baseline CEA serum levels below the statistical median of 26.8 ng/mL (group I) were compared with patients with higher CEA levels (group II). The cetuximab‐based treatment cohort was analyzed for specificity assessment of CEA to predict the anti‐vascular endothelial growth factor effect in mCRC. Baseline CEA serum levels inversely correlated with therapeutic response in patients receiving bevacizumab‐based treatment (disease control rate, 84% vs 60%), inversely correlated with median PFS leading to a median PFS benefit of 2.1 months for patients in group I when compared with group II, as well as inversely correlated with median overall survival (37.5 months vs 21.4 months). In an independent cohort of 129 patients treated with cetuximab‐based therapy, no association of therapeutic response or PFS with CEA serum levels was found. As expected, baseline CEA levels were prognostic for mCRC. These data give first evidence that baseline serum CEA levels might constitute an important predictor for the efficacy of first‐line bevacizumab‐based therapy in patients with mCRC.

• Publication year

  2014

• Venue

  Cancer Science

• Publication date

  2014-07-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/cas.12451PMID 24850362PMCID 4317865
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

  2023cited by this paper
• Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis.

  2013cited by this paper
• Markers of response for the antiangiogenic agent bevacizumab.

  2013cited by this paper
• Lessons from the adjuvant bevacizumab trial on colon cancer: what next?

  2011cited by this paper
• Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study).

  2010cited by this paper
• PlGF blockade does not inhibit angiogenesis during primary tumor growth.

  2010cited by this paper
• The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy.

  2010cited by this paper
• Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.

  2010cited by this paper
• Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy

  2010cited by this paper
• Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

  2008cited by this paper
• Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy

  2008cited by this paper
• Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

  2008cited by this paper
• FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

  2008cited by this paper
• Preoperative Serum Carcinoembryonic Antigen Level as a Predictive Factor of Recurrence After Curative Resection of Colorectal Cancer

  2008cited by this paper
• Multivariable Model-Building: A Pragmatic Approach to Regression Analysis based on Fractional Polynomials for Modelling Continuous Variables

  2008cited by this paper
• Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer.

  2008cited by this paper
• Carcinoembryonic antigen inhibits anoikis in colorectal carcinoma cells by interfering with TRAIL-R2 (DR5) signaling.

  2007cited by this paper
• GPI-anchored CEA family glycoproteins CEA and CEACAM6 mediate their biological effects through enhanced integrin alpha5beta1-fibronectin interaction.

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• GPI‐anchored CEA family glycoproteins CEA and CEACAM6 mediate their biological effects through enhanced integrin α5β1‐fibronectin interaction &

  2007cited by this paper
• Dichotomizing continuous predictors in multiple regression: a bad idea

  2006cited by this paper
• Clinical trial designs for predictive marker validation in cancer treatment trials.

  2005cited by this paper
• Angiogenesis in life, disease and medicine

  2005cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Angiogenesis in cancer and other diseases

  2000cited by this paper
• Human carcinoembryonic antigen functions as a general inhibitor of anoikis.

  2000cited by this paper
• Expression of CD66a (human C-CAM) and other members of the carcinoembryonic antigen gene family of adhesion molecules in human colorectal adenomas.

  1997cited by this paper
• The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer.

  1995cited by this paper
• The prognostic value of CEA, βHCG, AFP, CA125, CA19-9 and C-erb B-2, (βHCG immunohistochemistry in advanced colorectal cancer

  1995cited by this paper
• Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis.

  1990cited by this paper
• DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES

  1965cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• Survival impact of radiotherapy for patients with de novo metastatic rectal cancer

  2026influential citation
• ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ CỦA PHÁC ĐỒ MFOLFOX6 - BEVACIZUMAB TRÊN BỆNH NHÂN UNG THƯ ĐẠI TRÀNG GIAI ĐOẠN IV

  2026cites this paper
• Preoperative prediction and localization of synchronous metastases in colon cancer: the role of CECT combined with clinical characteristics

  2025cites this paper
• The application of different machine learning models based on PET/CT images and EGFR in predicting brain metastasis of adenocarcinoma of the lung

  2024cites this paper
• The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer

  2024cites this paper
• Long-term outcomes of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): a randomized, multicenter, prospective, phase III trial

  2024cites this paper
• Optimal patient selection for yttrium-90 glass plus chemotherapy in the treatment of colorectal liver metastases: additional quality of life, efficacy, and safety analyses from the EPOCH study

  2024cites this paper
• Prognosis of carcinoembryonic antigen (CEA) in stage I colorectal adenocarcinoma and development of a prediction model: a retrospective study based on the SEER database

  2023cites this paper
• Deep radiomics-based fusion model for prediction of bevacizumab treatment response and outcome in patients with colorectal cancer liver metastases: a multicentre cohort study

  2023cites this paper
• CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer

  2023cites this paper
• Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center

  2021cites this paper
• Prognostic factors in patients with complete response of the tumour (ypT0) after neoadjuvant chemoradiotherapy and radical resection of rectal cancer

  2021cites this paper
• Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer

  2021cites this paper
• Development and Validation of a Novel Serum Prognostic Marker for Patients with Metastatic Colorectal Cancer on Regorafenib Treatment

  2021cites this paper
• Advances in Biosensors and Diagnostic Technologies Using Nanostructures and Nanomaterials

  2021cites this paper
• AKP and GGT level can provide early prediction of first-line treatment efficacy in colorectal cancer patients with hepatic metastases.

  2021cites this paper
• Beneficiaries of radical surgery among clinical complete responders to neoadjuvant chemoradiotherapy in rectal cancer

  2021cites this paper
• Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy

  2021cites this paper
• Role of Tumour Markers CEA and CA19-9 in Colorectal Cancer

  2020cites this paper
• Ramucirumab in the second-line treatment of metastatic colorectal cancer: a narrative review of literature from clinical trials

  2020cites this paper
• The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer

  2019cites this paper
• Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).

  2019cites this paper
• Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer

  2019cites this paper
• Combination of D‐dimer and carcinoembryonic antigen levels as a predictive and prognostic biomarker in advanced colorectal cancer patients

  2019cites this paper
• Carcinoembryonic antigen reduction after medical treatment in patients with metastatic colorectal cancer: a systematic review and meta-analysis

  2019cites this paper
• Ramucirumab: the long and winding road toward being an option for mCRC treatment

  2019cites this paper
• Combination chemotherapy with TAS-102 plus bevacizumab in salvage-line treatment of metastatic colorectal cancer: A single-center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage-line therapy of metastatic colorectal cancer.

  2019cites this paper
• Opportunities for Antibody Discovery Using Human Pluripotent Stem Cells: Conservation of Oncofetal Targets

  2019cites this paper
• pMHC Structural Comparisons as a Pivotal Element to Detect and Validate T-Cell Targets for Vaccine Development and Immunotherapy—A New Methodological Proposal

  2019cites this paper
• The efficiency of collagen III, metalloproteinase 1, carcinoembryonic antigen, and carbohydrate antigen 19.9 for colon cancer diagnosis

  2019cites this paper
• Correlation between circulating endothelial progenitor cells and serum carcinoembryonic antigen level in colorectal cancer.

  2018cites this paper
• Tumor-associated Macrophages and Neuroendocrine Differentiation Decrease the Efficacy of Bevacizumab Plus Chemotherapy in Patients With Advanced Colorectal Cancer.

  2018cites this paper
• The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line

  2018cites this paper
• Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome

  2018influential citation
• Correlation between circulating endothelial progenitor cells and serum carcinoembryonic antigen level in colorectal cancer

  2018cites this paper
• A novel therapeutic strategy of personalized medicine based on anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer

  2018cites this paper
• Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response

  2018cites this paper
• Pre-treatment carcinoembryonic antigen and outcome of patients with rectal cancer receiving neo-adjuvant chemo-radiation and surgical resection: a systematic review and meta-analysis

  2017cites this paper
• Biomarkers for the early detection of relapses in metastatic colorectal cancers.

  2017cites this paper
• An investigation of volatile organic compounds as biomarkers for gastrointestinal neoplasia

  2017cites this paper
• Carcinoembryonic Antigen: a Multifunctional Molecule in Colorectal Cancer Progression and Metastasis

  2017cites this paper
• Serum CEA and CA 19-9 Levels are Associated with the Presence and Severity of Colorectal Neoplasia

  2017cites this paper
• Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.

  2017cites this paper
• Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed

  2017cites this paper
• Avoiding hepatic metastasis naturally: Lessons from the cotton top tamarin (Saguinus oedipus).

  2016cites this paper
• Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

  2015cites this paper
• Molecular Markers Predictive of Chemotherapy Response in Colorectal Cancer

  2015cites this paper
• IMAC capture of recombinant protein from unclarified mammalian cell feed streams

  2015cites this paper
• The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study

  2015cites this paper
• Alpha-1-acid glycoprotein as a potential biomarker of breast cancer in at risk individuals.

  2015cites this paper
• Reduction of plasma fibulin-1 predicts poor survival in metastatic colorectal cancer

  2015cites this paper
• Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens

  2014cites this paper
• Biomarker-driven studies in metastatic colorectal cancer (mCRC): Challenges and opportunities

  2014cites this paper